<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000413959"><TermName>Thymitaq</TermName><TermPronunciation>(THY-mih-tak)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of liver cancer. It belongs to the family of drugs called thymidylate synthase inhibitors. Also called AG337 and nolatrexed.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000713353" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Thymitaq&quot;" language="en" id="_3"/><MediaLink ref="CDR0000713352" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Thymitaq&quot;" language="es" id="_4"/><SpanishTermName>Thymitaq</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento del cáncer de hígado. Es un tipo de inhibidor de la timidilato de sintasa. También se llama AG337 y nolatrexed.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2005-05-23</DateFirstPublished><DateLastModified>2005-05-19</DateLastModified></GlossaryTerm>
